Purchase Order 75N92E20P00150

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation for $12,187.66 on August 21, 2020, for genotyping experiments. Performance is at Life Technologies' facility in Grand Island, New York. The order carries a firm fixed price and has an ultimate completion date of October 30, 2020. No set-aside category applies.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation valued at $4,452.00 on September 15, 2017, for firm fixed price commercial items. Place of performance is Bethesda, Maryland. The order has an ultimate completion date of December 31, 2017. No set-aside was used.</p>

The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation on March 30, 2020, with a ceiling value of $17,280.00 for firm fixed-price commercial supplies. Place of performance is Grand Island, New York. The order was scheduled for ultimate completion on July 25, 2020. No set-aside was used. Life Technologies, a subsidiary of Thermo Fisher Scientific, is a leading supplier of biomedical research tools, genetic analysis instruments, reagents, and...

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation for $4,427.49 on December 1, 2017, with ultimate completion by December 31, 2018. No set-aside was applied. Place of performance is Bethesda, Maryland. The order procures scientific supplies or equipment typical of Life Technologies' federal portfolio, which includes laboratory instrumentation, reagents, and consumables for genomic research applications.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Life Technologies Corporation (operating as Thermo Fisher Scientific) on January 21, 2020, with a ceiling value of $20,062.52 for service contract renewal under firm fixed pricing. Performance occurred in Bethesda, Maryland, with an ultimate completion date of February 20, 2021. No set-aside was applied to this order.</p>

<p>The National Human Genome Research Institute issued a $24,926.45 delivery order to Illumina, Inc. on September 19, 2019, under a firm fixed-price structure.</p> <p>Place of performance is Bethesda, MD. The order was due for completion on September 2, 2020. No set-aside was applied to this delivery order.</p>

<p>The National Human Genome Research Institute issued a $15,321.60 delivery order to Illumina, Inc. on July 18, 2019, for genetic sequencing equipment and related genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price structure with an ultimate completion date of September 2, 2020. No set-aside was used for this award.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Global Life Sciences Solutions USA LLC for a microtiter stage upgrade valued at $34,966.14 on September 16, 2020, with completion by November 30, 2020. Work is performed at the contractor's Marlborough, Massachusetts facility. The purchase order is firm fixed price with no set-aside designation. The solicitation was posted September 8, 2020, with award on the same date as the due date.</p>

<p>The National Human Genome Research Institute issued a delivery order to Illumina, Inc. on July 30, 2019, with a ceiling value of $246,062.25 for genetic sequencing equipment and related genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order was firm fixed price with no set-aside designation and an ultimate completion date of September 2, 2020.</p>

<p>The National Human Genome Research Institute issued a $98,905.32 delivery order to Illumina, Inc. on August 22, 2019, for genetic sequencing and genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD 20892. The order is firm fixed-price with an ultimate completion date of September 2, 2020. No set-aside was used.</p>